Ranopto
Ranibizumab biosimilar developed by Teva Canada. Reference product Lucentis.
Brands by market: Ranopto (Canada) · Commercial partner or holder: Teva Canada · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCOct 2023approved
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Ranopto
Ranopto is Teva's ranibizumab for Canada, approved in October 2023. Teva has not named the developer of the product, and it has no counterpart in the United States or Europe.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Ranopto
Health CanadaApprovedBrand
Ranopto
Holder or applicant
Teva Canada Limited
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Oct 2023
Application or permission
DIN 02542250
Presentations
10 mg
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Ranopto holds an approval, these are the other ranibizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| HC | 1 | Samsung Bioepis (Byooviz) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Teva: Ovaleap, Ponlimsi / Degevma, Teriparatide Teva, Tevagrastim / Ratiograstim.
Chronology
- HCOct 2023Notice of Compliance, Health Canada
Sources
Planning ranibizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.